MMED:CC News and Press, MIND MEDICINE INC. From 09/27/22

MindMed Announces Pricing of Public Offering of Common Shares and Warrants Canada NewsWire NEW YORK , Sept. 27, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. ("MindMed") (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel ...

MindMed Announces Proposed Public Offering of Common Shares Canada NewsWire NEW YORK , Sept. 27, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. ("MindMed") (Nasdaq: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products t...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 22, 2022 –  Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one week after San Francisco officially decriminali...

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances Canada NewsWire First-in-human trial to investigate the tolerability, pharmacology, and pharmacokinetics of novel MDMA-like compounds versus a placebo in heal...

MindMed Announces Compliance with Nasdaq Listing Requirements Canada NewsWire NEW YORK , Sept. 14, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing ...

MindMed Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal Canada NewsWire - Data from University Hospital Basel (UHB) study supports the clinical development of MindMed's proprietary MM-120...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 7, 2022 – According to a new survey by Johns Hopkins Medicine researchers, people’s attitudes toward death change after a psychedelic drug experience and a non-d...

MindMed to Participate in H.C. Wainwright Global Investment Conference Canada NewsWire NEW YORK , Sept. 7, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company dev...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder Canada NewsWire NEW YORK , Aug. 25, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage...

IIROC Trade Resumption - MMED Canada NewsWire TORONTO , Aug. 23, 2022 /CNW/ - Trading resumes in: Company: MIND MEDICINE (MINDMED) INC. NEO Exchange Symbol: MMED All Issues: No Resumption (ET): 9:39:10 AM IIROC can make a decision to i...